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Long: Foreword

Foreword
The Annals of Health Law & Life Sciences Editorial Board is proud
to present the Winter 2021 Issue, the first edition of our thirtieth
volume to date. Due to the global COVID-19 pandemic, the year 2020
was unprecedented in many respects, and doubly so in the health and
life sciences spaces. The pandemic forced individuals to isolate and
schools and businesses to operate virtually, yet scholarship persevered.
As the scale of the COVID-19 pandemic dawned upon the world,
scientific data and evidence became more important than ever for
institutions and individuals alike. As such, I am honored to introduce
the following works of scholarship which take a critical look at current
policies in health law and life sciences, and show a better way forward.

&

Combining economics with health policy, Alexander C. Davis's
The International Price Index's Impact on Revenue in the
Pharmaceutical Industry begins by analyzing the current economic
and regulatory policies in the pharmaceutical sphere. Davis introduces
the International Price Index, first proposed by former Health
Human Services Secretary Alex Azar in 2018 to reduce drug prices
under Medicare Part B. Davis outlines how the International Price
Index would set a ceiling on Medicare reimbursement for certain
drugs, putting pressure on other countries to be more flexible in their
price regulations of pharmaceuticals in order to reduce drug costs in
the United States. He acknowledges concerns that reducing
reimbursement for pharmaceuticals may stifle innovation, but argues
that marketing and other business expenses make up a greater share of
pharmaceutical companies' budgets than research and development,
and thus a reduction in reimbursement would not categorically stifle
innovation. Davis concludes that the International Price Index will
address the astronomical price of pharmaceuticals under Medicare Part
B without stifling innovation, and echoes Secretary Azar's advocacy
through his unique economic analysis.
In our second selection, Matthew R. Davison explores mental health
trials in Illinois and how virtual trials due to the COVID-19 pandemic
risk the violation of individuals' fundamental rights in No Ordinary
Process:

The Flaws in Illinois

Courts' Use of Remote

Video
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Technology in Mental Health Trials. Davison, an attorney for the State

of Illinois Guardianship & Advocacy Commission, examines the
experimental use of video technology in trials before cities and
municipalities were forced to shelter in place in 2020, and how
subsequent stay-at-home orders accelerated its implementation. He
focuses on important safeguards in mental health proceedings which
can be neglected in the push to go remote. Davison explores the
fundamental rights of these patients, their expectations of these trials,
and where Illinois policies have fallen short and contradicted one
another. Davison's piece is a crucial example of advocacy for those
whose voices often go unheard.
Walter G. Johnson's Catching Up with Convergence: Strategiesfor
Bringing Together the FragmentedRegulatory Governance of Brain-

Machine Interfaces In the United States next explores the world of
neurological technology, examines the evolution of brain-machine
interface devices, and suggests possible consequences of allowing this
technology to be developed without oversight. Johnson details the
fragmented regulation of this emerging technology, which can
variously come from the Food & Drug Administration, the Federal
Trade Commission, and even federal courts. After evaluating this fastgrowing industry and its patchwork regulation, Johnson proposes a
solution which would allow this technology to flourish, while also
providing consumers with the protections of a unified regulatory
scheme.
Finally, Dr. Julien Chaisse and Dr. Nilanjan Banik address health
governance in Global Health Law & Governance Amidst the
Pandemic. This timely work identifies the vulnerabilities the COVID19 pandemic exposed in various health systems, and introduces the
Health Infrastructure Index, a tool which uses metrics to better index
countries' health infrastructure. By applying indexing innovations to
their critical analysis of these complicated systems, Dr. Julien Chaisse
and Dr. Nilanjan Banik provide a solution to allow governments and
international agencies to better allocate funds and improve global
health overall, even amidst a pandemic.
On behalf of all staff members of Annals of Health Law and Life
Sciences, I would like to thank Alexander C. Davis, Matthew R.
Davison, Walter G. Johnson, Dr. Julien Chaisse, and Dr. Nilanjan
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Banik for bringing their extraordinary work in the field of health law
and life sciences to the pages of Annals. This issue shows that even in
the face of unprecedented global challenges, innovation, scholarship,
and advocacy persist. The Editorial Board and I would like to thank
each student editor at Annals for their dedication, scholarship, and
tenacity. Additionally, I would like to recognize the outstanding work
of Daniel Duffy, Annals Publications Editor, for his commitment to
exceptional scholarly work. Further, I would be remiss not to
recognize the remarkable effort of our Advance Directive and
Technical Editor, Peggy Frazier, who went above and beyond in
ensuring this issue was published. I would also like to thank Marketing
& Coordinating Editor, Natasha Shukla, for spearheading the curation
of these articles; Symposium Editor, Krystal Tysdal, and Advance
Directive Editors, Lauren Koch, and Harte Brick. Your tireless efforts
have brought this issue to life. Furthermore, I would like to recognize
and thank our remarkable Senior Editors: Mallory Burney, Raminta
Kizyte, Damyan Kolomayets, Nicole Harris, Julian Florio, and
Sunaina Ramesh. And finally, I would like to thank our supportive
advisors at the Beazley Institute for Health Law and Policy, including
Professors Nadia Sawicki and Kristin Finn, for their valued guidance.
Karin M. Long, Editor-in-Chief
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